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(7) Fellowships will be offered primarily for clinical training of
one to two years duration.
(8) Clinical training programs should be practical in their
orientation, and applicable to the needs and conditions of
the home country. The ability of the host institution to
provide such training will be an important factor in the
selection process.
(9) Fellows must have received sufficient training in internal
medicine or other fields to pass all host country examina-
tions that are necessary to the care of patients. Fellow-
ships may be awarded to senior individuals who seek
additional training but, in general, preference will be given
to younger physicians who are at the beginning of their
permanent careers.
(10) Specific instructions and the necessary application forms
can be obtained by writing directly to Jan J. Weening,
M.D., Academic Medical Center, Meibergdreef 9, 1105
AZ Amsterdam, The Netherlands.
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Errata
Edmands SD, Hughs KS, Lee SY, Meyer SD, Saari E, Yancey PH:
Time-dependent aspects of osmolyte changes in rat kidney, urine,
blood and lens with sorbinil and galactose feeding (Kidney mt
48:344—353, 1995).
The authors regret an error in Table 3. The correct table is
shown below.
Table 3. Contents of major osmolytes in lenses of rats, treated in four dietary groups for 10 and 42 days
Group N
Lens solute contentS, 10 days Lens solute contents, 42 days
Galactose Galacititol Galactose Galacititol
Galactose 5 2.20 1.32' 187 11.6 0.70 0.58" 107 23U
Sorbinil + galactose 5 2.47 0.93a 24.5 0.78 0.52 63.0 136ah
N indicates number of animals. Galactose contents are in mmol/kg wet wt (± SD), galactitol in mmol/kg (± SD; protein content of lenses averaged
32 5%). Control and Soi-binil groups (not shown) had no detectable levels of these solutes.
a Significantly different from Control group (P < 0.05, SNK multiple comparison tests)bSignificantly different from Galatose group (P < 0.05, SNK multiple comparison tests)
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KANWAR YS, Liu ZZ, KUMAR A, WADA J, and CARONE FA:
Cloning of mouse c-ros renal cDNA, its role in development and
relationship to extracellular matrix glycoproteins. Kidney mt 48:
1646—1659.
Due to a typesetting error, Fig. 7 in the article listed above was
misprinted. The correct figure is shown below. The printer regrets
the error.
Fig. 7. Competitive RT-PCR of c-ros cDNAs prepared from control (•, C,
lanes I to 4) and antisense-ODN-treated (, A, lanes 5 to 8) kidney explants
in metanephric culture. A reduction in the amplification of the PCR
products is observed in cDNAs prepared from antisense-treated kidneys.
The amplified PCR product is barely detectable even at the highest
dilution (1O8) of the competitive plasmid DNA. While in the control, the
amplified PCR product can be detected at the highest concentration
(1O) of competitive plasmid DNA.
